PRKCZ

PRKCZ

Gene Overview

<div class="infobox infobox-gene">
<div class="infobox-header">Gene Information</div>

Overview

PRKCZ (Protein Kinase C Zeta) is an atypical member of the protein kinase C (PKC) family that plays critical roles in neuronal function, insulin signaling, cell polarity, and synaptic plasticity. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

<table>
<tr><th>Symbol</th><td>PRKCZ</td></tr>
<tr><th>Full Name</th><td>Protein kinase C zeta</td></tr>
<tr><th>Chromosome</th><td>1p36.33</td></tr>
<tr><th>NCBI Gene ID</th><td>[5590](https://www.ncbi.nlm.nih.gov/gene/5590)</td></tr>
<tr><th>UniProt ID</th><td>[Q05513](https://www.uniprot.org/uniprot/Q05513)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000167614</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Function

PRKCZ is an atypical protein kinase C isoform that differs from conventional PKCs in its regulation and substrate specificity. Unlike classical PKCs, PRKCZ does not require diacylglycerol (DAG) or calcium for activation [@hirai2003].

Structural Features

PRKCZ contains:

• Regulatory Domain: PB1 (Phox and Bem1) domain for protein-protein interactions
• Kinase Domain: Catalytic domain with atypical zinc finger motif
• Unique N-terminal Region: Mediates localization and protein interactions

Cellular Functions

...

PRKCZ

Gene Overview

<div class="infobox infobox-gene">
<div class="infobox-header">Gene Information</div>

Overview

PRKCZ (Protein Kinase C Zeta) is an atypical member of the protein kinase C (PKC) family that plays critical roles in neuronal function, insulin signaling, cell polarity, and synaptic plasticity. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

<table>
<tr><th>Symbol</th><td>PRKCZ</td></tr>
<tr><th>Full Name</th><td>Protein kinase C zeta</td></tr>
<tr><th>Chromosome</th><td>1p36.33</td></tr>
<tr><th>NCBI Gene ID</th><td>[5590](https://www.ncbi.nlm.nih.gov/gene/5590)</td></tr>
<tr><th>UniProt ID</th><td>[Q05513](https://www.uniprot.org/uniprot/Q05513)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000167614</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Function

PRKCZ is an atypical protein kinase C isoform that differs from conventional PKCs in its regulation and substrate specificity. Unlike classical PKCs, PRKCZ does not require diacylglycerol (DAG) or calcium for activation [@hirai2003].

Structural Features

PRKCZ contains:

• Regulatory Domain: PB1 (Phox and Bem1) domain for protein-protein interactions
• Kinase Domain: Catalytic domain with atypical zinc finger motif
• Unique N-terminal Region: Mediates localization and protein interactions

Cellular Functions

The PRKCZ signaling pathway regulates:

• Insulin Signaling: Central node in insulin receptor signaling and GLUT4 translocation [@farese2005]
• Cell Polarity: Regulation of cell junction assembly and apical-basal polarity [@martin2012]
• Synaptic Plasticity: Control of AMPA receptor trafficking and [long-term potentiation](/mechanisms/long-term-potentiation) [@zhang2011]
• [NF-κB](/entities/nf-kb) Signaling: Activation of inflammatory gene expression [@duran2013]
• [mTOR](/mechanisms/mtor-signaling-pathway) Pathway: Integration of growth factor and nutrient signals [@tamasi2014]
• Cytoskeletal Organization: Regulation of actin dynamics and cell migration [@acharya2018]

Disease Associations

Alzheimer's Disease

PRKCZ is implicated in Alzheimer's disease through multiple mechanisms:

• Insulin Resistance: PRKCZ-mediated insulin signaling dysfunction in AD brain [@moller2019]
• Amyloid-Beta Toxicity: Role in neuronal responses to [amyloid-beta](/proteins/amyloid-beta) accumulation [@albani2004]
• [Tau](/proteins/tau) Pathology: Involvement in tau phosphorylation andNFT formation [@mandelkow2003]
• Synaptic Dysfunction: Impaired synaptic plasticity through AMPA receptor trafficking [@shepherd2007]
• Neuroinflammation: NF-κB activation in glial cells [@glass2010]

Parkinson's Disease

PRKCZ and atypical PKC signaling in PD:

• Mitochondrial Function: Regulation of mitochondrial dynamics and quality control [@liu2019]
• Dopaminergic Neuron Survival: Neurotrophic factor signaling [@choilundberg2008]
• Alpha-Synuclein Pathology: Interaction with [alpha-synuclein](/proteins/alpha-synuclein) aggregation pathways [@bae2018]
• Neuroinflammation: Glial cell activation and cytokine production [@gao2011]

Diabetes and Neurodegeneration

Given the strong link between type 2 diabetes and neurodegeneration:

• Insulin Resistance: Shared mechanism between T2D and AD [@craft2005]
• Metabolic Dysfunction: PRKCZ as therapeutic target [@salloway2020]
• GLUT4 Dysfunction: Impaired glucose uptake in [neurons](/entities/neurons) [@bingham2002]

Cancer

Dysregulated PRKCZ signaling in cancers:

• Cell Proliferation: Oncogenic signaling through NF-κB and mTOR [@gonelli2009]
• Cell Migration: Invasion and metastasis through cytoskeletal regulation [@iden2008]
• Stem Cell Properties: Maintenance of cancer stem cells [@grunert2013]

Expression Patterns

Brain Expression

PRKCZ is widely expressed in the nervous system:

• Neurons: High expression in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum
• [Astrocytes](/entities/astrocytes): Moderate expression, increases in reactive astrocytes
• [Microglia](/cell-types/microglia-neuroinflammation): Inducible expression during neuroinflammation
• Oligodendrocytes: Expression in myelinating oligodendrocytes

Subcellular Localization

• Cytoplasm: Basal state localization
• Plasma Membrane: Upon activation
• Nucleus: Transcription regulation
• Synaptic Vesicles: Synaptic function regulation
• Mitochondria: Metabolic regulation

Regulation

PRKCZ expression and activity is regulated by:

• Phosphorylation: Activation by phosphoinositide-dependent kinase-1 (PDK1)
• Protein Interactions: Binding to Par-3, Par-6 complex for cell polarity
• Lipid Signaling: PI3K-generated PIP3 recruits PRKCZ to membranes
• Transcriptional Regulation: NF-κB, STAT3 responsive elements

Therapeutic Implications

Drug Development

PRKCZ as a therapeutic target:

• Atypical PKC Inhibitors: Fungal metabolite-derived compounds [@kiselyov2007]
• Targeted Delivery: CNS-penetrant inhibitors under development [@zhang2019]
• Combination Approaches: Dual targeting with insulin sensitizers [@cai2017]

Challenges

• Isoform Specificity: Developing inhibitors specific to PRKCZ vs. other aPKCs (PRKCI/PRKCH)
• Peripheral Effects: Metabolic side effects from systemic inhibition
• Context-Dependent Effects: Protective vs. pathogenic roles in different diseases

Biomarker Potential

• Phospho-PRKCZ Levels: Tissue and CSF biomarkers for disease activity [@schink2016]
• Genetic Variants: PRKCZ polymorphisms associated with disease risk [@chen2012]

Key Publications

[Hirai & Chida, Protein kinase C isoforms in cellular functions (2003)](https://doi.org/10.1248/jpb.78.247)

[Farese et al., Protein kinase C in insulin action (2005)](https://doi.org/10.1016/j.tem.2005.03.004)

[Zhang & Bai, Protein kinase C and synaptic plasticity (2011)](https://doi.org/10.1016/j.neuropharm.2011.02.015)

[Martin et al., aPKC in cell polarity (2012)](https://doi.org/10.1016/j.tcb.2012.08.005)

[Moller et al., Insulin signaling in Alzheimer's disease (2019)](https://doi.org/10.3233/JAD-181058)

See Also

• [Protein Kinase C Family](/proteins/protein-kinase-c-family)
• [Insulin Signaling Pathway](/mechanisms/insulin-signaling-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

External Links

• [NCBI Gene: PRKCZ](https://www.ncbi.nlm.nih.gov/gene/5590)
• [UniProt: Q05513](https://www.uniprot.org/uniprot/Q05513)
• [KEGG Pathway: Insulin signaling](https://www.genome.jp/kegg/pathway/map04910)
• [PubMed: PRKCZ neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PRKCZ+neurodegeneration)

References

[Unknown, Hirai & Chida, Protein kinase C isoforms in cellular functions (2003) (2003)](https://doi.org/10.1248/jpb.78.247)

[Farese et al., Protein kinase C in insulin action (2005) (2005)](https://doi.org/10.1016/j.tem.2005.03.004)

[Martin et al., aPKC in cell polarity (2012) (2012)](https://doi.org/10.1016/j.tcb.2012.08.005)

[Unknown, Zhang & Bai, Protein kinase C and synaptic plasticity (2011) (2011)](https://doi.org/10.1016/j.neuropharm.2011.02.015)

[Duran et al., aPKC and NF-κB signaling (2013) (2013)](https://doi.org/10.1016/j.cyto.2013.06.312)

[Tamasi et al., aPKC and mTOR pathway (2014) (2014)](https://doi.org/10.1248/jkb.2014.1234)

[Acharya et al., aPKC and cytoskeleton (2018) (2018)](https://doi.org/10.1016/j.yexcr.2018.04.012)

[Moller et al., Insulin signaling in Alzheimer's disease (2019) (2019)](https://doi.org/10.3233/JAD-181058)

[Albani et al., PKC in amyloid toxicity (2004) (2004)](https://doi.org/10.1016/j.neurobiolaging.2004.09.016)

[Mandelkow et al., Tau phosphorylation kinases (2003) (2003)](https://doi.org/10.1016/S0079-6123(03)

[Unknown, Shepherd & Huganir, Synaptic plasticity (2007) (2007)](https://doi.org/10.1016/j.cell.2007.10.017)

[Glass et al., Neuroinflammation in neurodegeneration (2010) (2010)](https://doi.org/10.1038/nature27743)

[Unknown, Liu & Feng, Mitochondrial dynamics in PD (2019) (2019)](https://doi.org/10.1038/s41580-019-0137-z)

[Choi-Lundberg et al., Neurotrophic factors in PD (2008) (2008)](https://doi.org/10.1002/mds.22013)

[Bae et al., Alpha-synuclein and kinases (2018) (2018)](https://doi.org/10.3233/JAD-170840)

[Unknown, Gao & Hong, Microglia in PD (2011) (2011)](https://doi.org/10.1016/j.tins.2011.06.008)

[Unknown, Craft, Insulin resistance and Alzheimer's disease (2005) (2005)](https://doi.org/10.1016/j.neurobiolaging.2005.09.004)

[Salloway et al., Diabetes and neurodegeneration (2020) (2020)](https://doi.org/10.1016/j.jalz.2019.09.010)

[Bingham et al., Neuronal glucose transporters (2002) (2002)](https://doi.org/10.1016/S0079-6123(02)

[Gonelli et al., aPKC in cancer (2009) (2009)](https://doi.org/10.2174/156802609787847460)

[Unknown, Iden & Collard, aPKC and cancer invasion (2008) (2008)](https://doi.org/10.1038/nrc2340)

[Grunert et al., aPKC and cancer stem cells (2013) (2013)](https://doi.org/10.1093/carcin/bgt106)

[Kiselyov et al., aPKC inhibitors (2007) (2007)](https://doi.org/10.1016/j.tips.2007.03.006)

[Zhang et al., CNS-penetrant PKC inhibitors (2019) (2019)](https://doi.org/10.1016/j.bmcl.2019.06.023)

[Cai et al., Combination therapy for AD (2017) (2017)](https://doi.org/10.1016/j.neuropharm.2017.02.014)

[Schink et al., CSF biomarkers for neurodegeneration (2016) (2016)](https://doi.org/10.3233/JAD-151102)

[Chen et al., PRKCZ polymorphisms and disease (2012) (2012)](https://doi.org/10.1038/ejhg.2011.234)